Methotrexate, an inhibitor of dihydrofolate reductase, was reported to show synthetic lethality in MSH2-deficient cancer cells [38] and is currently in clinical trials for MSH2-deficient colorectal cancer (www.clinicaltrials.gov; Identifier: NCT00952016). The gene discussed is MSH2; the disease is colorectal cancer.